Mumbai-based pharmaceutical firm Glenmark Pharmaceuticals said it received final approval from the US Food and Administration (USFDA) for the sale of a generic version of Valeant Bermuda’s acne treatment, BenzaClin.
Clindamycin and benzoyl peroxide gel is a combination of clindamycin, an antibiotic and benzoyl peroxide, an antiseptic.
The gel is mainly used on the skin to prevent and treat acne in people above the age of 12.
Glenmark said that it now has 151 products authorised for distribution in the US and 53 applications pending with the FDA.
Established in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, Glenmark today has 16 manufacturing facilities in Europe, India and the U.S., operating under Good Manufacturing Practices.